Molecular Classification of Operable, non-distant Metastatic Breast Cancer in Mahasarakham Hospital.
Article Sidebar
Main Article Content
Abstract
Background: Breast cancer is the most common cancer in general practice. There are many studies of molecular classification in breast cancer but different outcome in each study up on ethnicity and region.
Objective: To study molecular classification of breast cancer in Mahasarakham Hospital and prognosis comparison of different molecular subtypes.
Methods: Research design is analytic study by retrospective data collection. The 110 patients who were diagnosed with breast cancer underwent modified radical mastectomy with immunohistochemistry stains of ER, PR, HER2 and Ki-67, between 1st January 2013 and 31st December 2015 were reviewed.
Result: All patients are women. Age ranges from 32 to 83 years (mean 53.9+/- 10.5 years). ER positive is 61.8%, PR positive is 50.9%, HER-2 positive is 44.5% and Ki-67 ranges from 1% to 70%. Fifty nine percent are alive and 40.9% are dead. Mean of overall survival is 2,082.1 +/- 937.4 days, mean of disease-free survival is 2,261.2 +/-904.9 days, 5-year survival is 66.4%. Molecular classification show Luminal A is 24.5%, Luminal B is 40% (Luminal B/HER2- is 16.4%, Luminal B/HER2+ 23.6%), HER2-enriched is 20.9% and Triple negative is 14.5% The difference of overall survival of each type is statistically significant. The overall survival of Luminal A is the highest, and overall survival of Triple negative and HER2-Enriched are lower than luminal type.
Discussion and conclusion: This study of molecular classification of breast cancer shows LuminalB is the most common type. The difference of overall survival of each type is statistically significant. The overall survival of Luminal A is highest, and overall survival of HER2-Enriched is low.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660.
Rojanamatin J, Ukranun W, Supaattagorn P. Edited. Cancer in Thailand Vol X. Bangkok: Rumthaipress; 2021.
Aldrees R, Gao X, Zhang K, Siegal GP, Wei S. Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution. Mod Pathol 2021;34(2):291-9. doi: 10.1038/s41379-020-00650-4.
Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012;19(1):39-53. doi: 10.1097/PAP.0b013e31823fafa0.
Numprasit w, Chowchankit I, Chuthapisith S. Warnnissorn M, Imruetaicharoenchoke W. Molecular Subtypes of Ductal Carcinoma In Situ (DCIS) Identified by Expression of ER, PR, HER2, and Ki-67. SMJ 2019;71(6):432–7. DOI: https://doi.org/10.33192/Smj.2019.64
Mohamed A, Al-Tamimi Dalal M, Ahmed Ayesha. Molecular classification of breast cancer: An overview with emphasis on ethnic variations and future perspectives. Saudi J Med Med Sci 2013;1(1):14. DOI: 10.4103/1658-631X.112908
Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathological features of indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev 2014;15(15):6109-13. doi: 10.7314/apjcp.2014.15.15.6109.
Paramita S, Raharjo EN, Niasari M, Azizah F, Hanifah NA. Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia. Asian Pac J Cancer Prev 2019;20(8):2247-52. doi: 10.31557/APJCP.2019.20.8.2247.
Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev 2012;13(2):459-62. doi: 10.7314/apjcp.2012.13.2.459.
Sripan P,Sriplung H,Pongnikorn D, Bilheem S, Virani S, Waisri N, et al. Clinical subtypes of breast cancer in Thai women: a population-based study of Chiang Mai province Asian Biomed (Res Rev News) 2019; 13(1):11–7. DOI 10.1515/abm-2019-0034.
Koonmee S, Somintara O, Intarawichian P, Aphivatanasiri C, Sangkhamanon S, Laohawiriyakamol S, et al. Pathum Raksa Project: Addressing Disparity in Breast Cancer Care Through National Innovation in Thailand. Cancer Manag Res 2021;13:8737-53. doi: 10.2147/CMAR.S335386.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22(8):1736-47. doi: 10.1093/annonc/mdr304.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018;142(11):1364-82. doi: 10.5858/arpa.2018-0902-SA
Mehdi I, Monem AA, Al Bahrani B, Ramadhan FA. Breast cancer molecular subtypes in oman: correlation with age, histology, and stage distribution - analysis of 542 cases. Gulf J Oncolog 2014;1(15):38-48.
Cheng HT, Huang T, Wang W, Yue JQ, Shen N, Guo H, et al. Clinicopathological features of breast cancer with different molecular subtypes in Chinese women. J Huazhong Univ Sci Technolog Med Sci 2013;33(1):117-21. doi: 10.1007/s11596-013-1082-2.
Fourati A, Boussen H, El May MV, Goucha A, Dabbabi B, Gamoudi A, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol 2014;10(2):e69-74. doi: 10.1111/ajco.12034.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
Al-Thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. Ann Med Surg (Lond) 20196;49:44-8. doi: 10.1016/j.amsu.2019.11.021
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350-60. doi: 10.1200/JCO.2005.03.3845
Jones RL, Constantinidou A, Reis-Filho JS. Molecular Classification of Breast Cancer. Surg Pathol Clin 2012;5(3):701-17. doi: 10.1016/j.path.2012.06.008
Alizart M, Saunus J, Cummings M,. Lakhani SR. Molecular classification of breast carcinoma. Diagn Histopathol 2012;18(3):97–103. DOI:https://doi.org/10.1016/j.mpdhp.2011.12.003
Liao GS, Hsu HM, Chu CH, Hong ZJ, Fu CY, Chou YC, et al. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. J Med Sci 2018;38(2):54. DOI: 10.4103/jmedsci.jmedsci_105_17
